Healthcare For HCPs

MYELOPROLIFERATIVE NEOPLASMS

LANDMARK SURVEY

For US Healthcare Professionals Only

The MPN LANDMARK SURVEY is a large-scale analysis of MPN patients and physicians. It provides a baseline of new data to advance scientific knowledge in order to further improve care for patients with MPNs, a group of rare, closely related blood cancers.

The ground-breaking survey was designed in collaboration with an external steering committee of MPN experts and thought leaders. Committee members included MPN specialists, allied health providers, patient advocacy group members, epidemiologists, and survey experts. The group investigated patient and physician experiences for the three most common MPNs:

  • Myelofibrosis (MF)
  • Polycythemia vera (PV)
  • Essential thrombocythemia (ET)

The survey also offers insights into patients' real-world needs.

Information from the report is available in three comprehensive data summaries.

The MPN LANDMARK SURVEY was funded by Incyte Corporation.


Click below to view publications regarding the MPN LANDMARK SURVEY

Differences in MPN Treatment Goals and Perception of Symptom Burden

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

MPNs Have a Significant Impact on Patients' Overall Health and Productivity

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ASH Abstract 1

Reproduced with permission from American Society of Hematology. Copyright 2014.

ASH Abstract 2

Reproduced with permission from American Society of Hematology. Copyright 2014.

Dr. Ruben Mesa Discusses Findings From the MPN Landmark Survey
Dr. Ruben Mesa Discusses Findings From the MPN Landmark Survey
Sara Goldberger Discusses Insights From the MPN Landmark Survey
Dr. Jim Mangan Discusses Findings From the MPN Landmark Survey
Maureen Thyne Discusses Findings From the MPN Landmark Survey
Dr. Salman Fazal Discusses Findings From the MPN Landmark Survey


Download summaries for healthcare professionals
Download MF Executive Summary

MF

Executive Summary

Download PV Executive Summary

PV

Executive Summary


1. Mesa R, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myleoproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2016. (doi:10.1002/cncr.30325).

2. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: The MPN Landmark survey. BMC Cancer. 2016;16:167. (doi: 10.1186/s12885-016-2208-2).